Since 1941, the Edward S. Harkness Eye Institute at the Columbia University Department of Ophthalmology has offered an ophthalmology basic science course. While the focus of the course is resident training, it has also proven useful for the visual sciences community as a whole. Coursework examines the fundamentals of vision and emphasizes how these basic principles relate to patient care.
On World Sight Day, eye care organisations around the world take note of new data that shows that global eye care efforts are at serious risk of being overwhelmed—unless we act now.
New data published in the Lancet Global Health shows that decades of declining “avoidable blindness”—those with uncorrected refractive errors and cataract—is plateauing, and is projected to increase between 2015 and 2050.
Novartis has reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two Phase III studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These pivotal studies enrolled more than 1,800 patients with neovascular age-related macular degeneration (nAMD) across 400 centres worldwide.
NEI 3-D Retina Organoid Challenge spurs next-generation models to study blinding diseases and test therapies
A proposal to create a living model of the human retina, the light-sensitive tissue at the back of the eye, won $90,000 in the National Eye Institute (NEI) 3-D Retina Organoid Challenge (3-D ROC). The NEI 3-D ROC is an initiative that seeks to design human retinas from stem cells. Erin Lavik, Sc.D., at the University of Maryland, Baltimore County, led the awarded team. The NEI is part of the National Institutes of Health.
A Symposium in honor of Dr. Gustavo Aguirre, recipient of the 2017 Proctor Medal, Association for Research in Vision and Ophthalmology (ARVO) will take place on Thursday November 16, 2017; 1:00pm—6:00pm at the School of Veterinary Medicine, University of Pennsylvania Please visit http://TRRaTConference.website2.me
Attendance is free but registration is essential to secure a place.
MeiraGTx, a New York and London based gene therapy company, have announced the first patient in its clinical study for X-Linked Retinitis Pigmentosa (XLRP) was treated at Moorfields Eye Hospital in London. This clinical study is the first-in-man Phase I/II dose escalation study of AAV2/5-hRKp.RPGR, MeiraGTx’s AAV-mediated gene therapy for XLRP caused by mutations in the RP GTPase regulator gene (RPGR).
Retina International will host its annual EURetina Symposium from 9am to 10.30am on Thursday September 7th in room 124 of the Barcelona Convention Centre.
The symposium will feature presentations on the European Reference Network for Rare Eye Disease (ERN-EYE), results from a recent study on the Economic Burden of Blindness in Europe, Patient Reported Outcome Measures for the retina and an introduction to the Retina International toolkit on genetic testing.
Potential for first gene therapy for a genetic disease to be approved in both the U.S. and EU
ESASO a School based at the ESASO Training Centre (ETC), Lugano Campus, Switzerland has published her preliminary Programme 2017.
Each module offers theoretical and practical tuition; all lessons are very interactive.
THE KEY ELEMENT THAT IGNITED MY BLIND SONS TO ACHIEVE GREATNESS